Please use this identifier to cite or link to this item: http://hdl.handle.net/11690/1780
Authors: Veiga, Viviane C.
Prats, João A. G. G.
Farias, Danielle L. C.
Rosa, Regis G.
Dourado, Leticia K.
Zampieri, Fernando G.
Machado, Flávia R.
Lopes, Renato D.
Berwanger, Otavio
Azevedo, Luciano C. P.
Avezum, Álvaro
Lisboa, Thiago
Rojas, Salomón S. O.
Coelho, Juliana C.
Leite, Rodrigo T.
Carvalho, Júlio C.
Andrade, Luis E. C.
Sandes, Alex F.
Pintão, Maria C. T.
Castro Junior, Claudio G.
Santos, Sueli V.
de Almeida, Thiago M. L.
Costa, André N.
Gebara, Otávio C. E.
Freitas, Flávio G. Rezende de
Pacheco, Eduardo S.
Machado, David J. B.
Martin, Josiane
Conceição, Fábio G.
Siqueira, Suellen R. R.
Damiani, Lucas P.
Ishihara, Luciana M.
Schneider, Daniel
Souza, Denise de
Cavalcanti, Alexandre B.
Scheinberg, Phillip
Title: Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Keywords: COVID-19
Issue Date: 2021
Publisher: BMJ Publishing Group
Citation: VEIGA, V. C. et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, v. 372, n. 84, jun. 2021. Disponível em: http://hdl.handle.net/11690/1780. Acesso em: 08 jul. 2021.
Appears in Collections:Artigo de Periódico (PPGSDH)

Files in This Item:
File Description SizeFormat 
Effect Tocilizumab_BMJ.pdfOpen Access421.25 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.